Navigation Links
Amicus Therapeutics Announces Third Quarter 2008 Financial Results
Date:11/3/2008

g of conducting clinical trials of AT2220 and ERT combination therapy; (ii) statements regarding the timing and goals of discussions with U.S. and EU regulatory authorities on the Phase 3 study and regulatory pathway for Amigal; (iii) statements on the goals, progress and timing of preclinical studies in Parkinson's disease and other research efforts aimed at evaluating disease targets in neurodegenerative and other genetic disorders; (iv) statements on the range of "cash burn" for Amicus in 2008, the need to raise additional capital in 2008 and the trends for incurring research and development expense in 2008; and (v) statements regarding expected milestone and research reimbursement payments from Shire. These forward-looking statements are based on the current estimates and assumptions of the management of Amicus as of the date of this press release and the conference call and are subject to risks, changes in circumstances, assumptions and uncertainties and other factors that may cause the actual results of Amicus to be materially different from those reflected in the forward-looking statements. Important factors that may cause actual results to differ materially from those indicated by forward-looking statements include, among others:

-- the potential that results of clinical or preclinical studies indicate

that product candidates are unsafe or ineffective,

-- our dependence on third parties in the conduct of our clinical studies,

-- a change in strategy by our collaboration partners,

-- delays or failure to achieve final agreement with regulatory

authorities on the design of phase 3 program for Amigal and the

regulatory pathway for approval of Amigal,

-- delays or failure to achieve regulatory approvals for our products,

-- risks of relying on third party manufacturers for the supply of our

product candidates,

-- our or licensors' inability to obtain, maintain and successfully<
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Amicus Therapeutics Announces Third Quarter 2008 Results Release Date
2. Amicus Therapeutics to Present at the 2008 UBS Global Life Sciences Conference
3. Amicus Therapeutics Opens Research Facility in San Diego
4. Amicus Therapeutics to Present at the 2008 BioCentury NewsMakers in the Biotech Industry Conference
5. Amicus Therapeutics Announces Second Quarter 2008 Results Release Date
6. Amicus Therapeutics Announces First Quarter 2008 Financial Results
7. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
8. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
11. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... 2014 /CNW/ - Aequus Pharmaceuticals Inc. (the "Company" ... has closed a brokered private placement offering (the ... million.  Cormark Securities Inc. and Clarus Securities Inc. ... for a syndicate of agents that also included ... the "Agents"). Concurrently with the Brokered Offering, the ...
(Date:11/18/2014)... BRUNO, Calif. , Nov. 18, 2014 ... a platinum sponsor of the 10th Annual World Stem Cell ... regenerative medicine stakeholders. The 2014 World Stem Cell Summit will ... San Antonio, Texas . The ... discovery and development of lifesaving cures and therapies, convening the ...
(Date:11/18/2014)... November 17, 2014 pH measurement and ... across the pharmaceutical, chemical, and food and beverage industries. ... important, and how do pH sensors work? METTLER TOLEDO ... those in process industries with these questions and more. ... measurement in the process industries. The actual sensor, the ...
(Date:11/18/2014)... 2014 American Process Inc. (Atlanta, ... a partnership with researchers at Georgia Institute of ... and the USDA’s Forest Products Laboratory to develop ... Nanocellulose is a rapidly emerging high performance nanomaterial ... is to replace heavy steel structures within cars, ...
Breaking Biology Technology:Aequus Pharmaceuticals closes $4.2 million private placement financing 2Aequus Pharmaceuticals closes $4.2 million private placement financing 3Cord Blood Registry Sponsors 2014 World Stem Cell Summit 2Cord Blood Registry Sponsors 2014 World Stem Cell Summit 3pH Guide from METTLER TOLEDO Explains Measurement, Theory and Practice of pH Applications 2American Process Inc. Announces Partnership to Develop Ultra-Strong, Lightweight Automotive Components Using Nanotechnology from Nature 2American Process Inc. Announces Partnership to Develop Ultra-Strong, Lightweight Automotive Components Using Nanotechnology from Nature 3
... VIA Pharmaceuticals,Inc. (Nasdaq: VIAP ), a ... the treatment of cardiovascular disease, announced today, in,compliance ... report included in the Company,s Annual Report on ... 2007 and filed with the Securities and,Exchange Commission ...
... Global Pharmaceutical Company Supports Organization,s National Networking ... ... Diversity Alliance for,Science, Inc. (DA4S) (http://www.diversityallianceforscience.com ) has announced,that Merck ... inaugural,networking conference and expo scheduled for May 19-20 at the Westin,Governors ...
... VIENNA, Austria, March 28 f-star, ... antibody fragments,based on its unique Modular Antibody ... royalty obligations to New Century Pharmaceuticals,(NCP) via ... was originally developed by Prof. Florian,Rueker, one ...
Cached Biology Technology:VIA Pharmaceuticals Complies With NASDAQ Rule 2VIA Pharmaceuticals Complies With NASDAQ Rule 3Merck & Co., Inc. Named Keynote Sponsor For Diversity Alliance For Science's Inaugural Conference 2Antibody Engineering Company F-Star Buys Back Royalty Obligations 2
(Date:11/6/2014)... 6, 2014 - Insilico Medicine, Inc, a Baltimore-based ... age related diseases announced a research collaboration with ... Champions Oncology, Inc (OTC: CSBR). , "There are ... medicine, but Champions Oncology,s TumorGraft technology is unique ... chemotherapy regimen experimentally generating vast amounts of valuable ...
(Date:11/4/2014)... Nov. 5, 2014 – University of Utah engineers developed ... help jet fuel produce electricity without needing to ignite ... to power portable electronics, off-grid power and sensors. , ... in the American Chemical Society journal ACS Catalysis ... a chemical reaction between a fuel and an oxygen-rich ...
(Date:11/4/2014)... only marketing directed at children on the interior ... that the majority of black, middle-income and rural ... , Authored by Arizona State University researcher Punam ... first to examine the use of child-directed marketing ... restaurants and its relationship to demographics. It adds ...
Breaking Biology News(10 mins):Insilico Medicine, Inc announces research collaboration with Champions Oncology, Inc 2Jet-fueled electricity at room temperature 2Fast food marketing for children disproportionately affects certain communities 2Fast food marketing for children disproportionately affects certain communities 3
... defeat natural forces? Specialist ants are capable of running on ... and food supplies. Some Macaranga trees in South East Asia ... insects. Only one specific ant is capable of running up ... and food supply inside the stem. , Tanja Bruening and ...
... on new methods to regenerate cartilage and bone by ... instruct them to turn into bone cells. The research, ... (BBSRC), could lead to a new approach to tissue ... holds the potential of significant benefits for patients needing ...
... based on infection with a specially designed virus similar to ... in clinical trials. Now, new research suggests that fever might ... study, published in the July issue of Cancer Cell, demonstrates ... after they have been incubated at an elevated temperature. The ...
Cached Biology News:New research could help us deliver genes for new bone formation 2Elevated temperature enhances success of viral cancer therapy 2
... for determination of baculovirus titers in just 2448 ... methods. Classical determination of baculovirus titer has relied ... Kit takes advantage of the appearance of detectable ... surface as early as 824 hours post-infection. Detection ...
... Thermocycler combines top performance with exquisite design. ... speed and unparalleled temperature uniformity. The instrument ... in a spreadsheet or alternatively in a ... opens on the push of a button ...
...
... an advanced system for isolating DNA from agarose gels ... directly for any downstream application. Features ... in 56 minutes Low melting point agarose not ... gels No specialised equipment required DNA is ...
Biology Products: